Exposure to light could help Alzheimer's patients sleep better

July 19, 2012 in Alzheimer's disease & dementia

Exposure to light could help alzheimer's patients sleep better

Enlarge

(Medical Xpress) -- Individuals with Alzheimer’s disease and related dementias (ADRD) often sleep during the day and are awake at night. The situation can turn life-threatening if they leave their homes and wander around outside. This irregular sleep schedule and night wandering, and the consequent burden on their caretakers, is a primary reason individuals with ADRD are placed in more controlled environments such as nursing homes. A new study from the Lighting Research Center (LRC) at Rensselaer Polytechnic Institute lays the foundation for the importance of tailored light exposures as a viable treatment option for the reduction of sleep disturbances in older adults and those with ADRD.

Funded by a grant from the National Institute on Aging (NIA), the study is the first to collect circadian light exposures in individuals with ADRD. Results of the quantitative study show that individuals with ADRD experienced lower light levels, exhibited lower activity levels, and had greater disruption to their natural circadian rhythms than healthy older adults. The findings also show that people with ADRD experience lower levels of light exposure and greater levels of circadian disruption during the winter.

“We used light/dark and activity/rest patterns to assess circadian disruption and our results are consistent with previous studies. However, this is the first field study to examine the synchrony between the circadian light pattern and the activity response pattern to assess circadian disruption,” said Mariana Figueiro, associate professor at Rensselaer and director of the Light and Health Program at the LRC, who led the study. “Measurements revealed that those with ADRD experienced more circadian disruption than healthy older adults.”

Results of the study, titled “Field Measurements of Light Exposures and Circadian Disruption in Two Populations of Older Adults,” will appear in the Journal of Alzheimer’s Disease. Figueiro presented the research team’s findings at the Alzheimer’s Association International Conference in Vancouver on July 17.

Along with Figueiro, co-authors of the study are LRC Director and Professor Mark S. Rea, LRC Research Specialist Robert Hamner, along with Patricia Higgins and Thomas Hornick, clinicians at Case Western Reserve University and Louis Stokes Cleveland VA Medical Center in Cleveland, Ohio.

Growing evidence indicates that circadian disruption by irregular light/dark patterns is associated with reduced quality of life and increased risk of disease. Circadian rhythms are governed by the human body’s master clock in what is known as the suprachiasmatic nuclei (SCN), which has an intrinsic period slightly longer than 24 hours. On average, the SCN runs with a period of 24.2 hours. Light/dark patterns on the retina, the photosensitive part of the eye, synchronizes the SCN to the 24-hour solar day, regulating biological rhythms such as when we are active and when we sleep. Without exposure to a regular, daily pattern of light and dark, circadian rhythms can become irregular.

“Biology is driven by circadian rhythms at every level, and light is the main stimulus for synchronizing the circadian system to the solar day. By quantifying an individual’s light/dark exposure pattern, we can prescribe ‘light treatments’ promoting circadian entrainment, thereby improving health and well-being,” said Figueiro.

To collect data for the study, the research team used a Dimesimeter, a dime-sized device developed by the LRC, to record how much photopic and circadian light an individual is exposed to and whether they are active or resting. The data-logging device records these light and activity levels continuously over many days, and can be easily attached to shirt collars, lapels, hats, wristbands, or eyeglasses. The Dimesimeter enables researchers to examine light/dark and activity/rest patterns in those experiencing circadian sleep disorders, such as Alzheimer’s patients. Data from the device can be downloaded to a computer and processed to calculate a cross-correlation of the activity/rest and light/dark exposure data, a measure of circadian entrainment/disruption.

“The Dimesimeter system allows researchers to accurately measure light/dark exposure and activity/rest patterns to quantify circadian disruption. In this way, we can collect ecological data on populations who suffer from circadian sleep disorders,” said Rea. “This new study using the Dimesimeter is a major step toward the goal of better understanding the impact of circadian disruption on human health.”

For the new NIA-funded study, the research team enlisted 16 healthy older adults and 21 adults with ADRD to wear a Dimesimeter on their wrists for one week. The research team in Cleveland collected data from those with ADRD and the research team in Troy collected the data from healthy . From the resulting data, the researchers calculated two metrics for each subject: relative activity (RA) to measure activity, and phasor magnitude to measure both light exposure and activity. The analysis revealed that during winter, those with ADRD exhibited more circadian disruption than healthy adults as reflected by their significantly shorter phasor magnitudes and lower RA values. Those with ADRD studied in winter also had significantly shorter phasor magnitudes than those studied in summer. ADRD adults were less active during waking hours than healthy adults, and ADRD adults studied in winter were exposed to less light than healthy adults in winter and ADRD adults in summer. The research team is currently delivering a lighting intervention to those with ADRD and their caretakers and measuring its impact on their sleep efficiency and circadian disruption.

Looking forward, the Dimesimeter could one day allow physicians to predict the optimum timing of the light therapy necessary to resynchronize the circadian phase with the solar day. Such treatments could range from going outdoors for 15 minutes to sitting in front of a box fitted with blue LEDs for a prescribed amount of time, according to Figueiro.

Last year, international magazine The Scientist named the LRC’s Dimesimeter as one of the “ Top 10 Innovations of 2011.”

Journal reference: Journal of Alzheimer's Disease search and more info website

Provided by Rensselaer Polytechnic Institute search and more info website

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

Home Care Assistance
Jul 26, 2012

Rank: not rated yet
To learn more about how in-home caregivers can assist with all aspects of an older adult's home life, please visit our Youtube Channel at homecareinfo and watch the video "Changing the Way the World Ages."
Rank not rated yet
Relevant PhysicsForums posts

More news stories

Scientists discover cinnamon compounds' potential ability to prevent Alzheimer's

Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...

Alzheimer's disease & dementia created 1 hour ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Drug reverses Alzheimer's disease deficits in mice, research confirms

An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.

Alzheimer's disease & dementia created 3 hours ago | popularity not rated yet | comments 0 | with audio podcast

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Alzheimer's disease & dementia created 3 hours ago | popularity not rated yet | comments 0 | with audio podcast

Major human drug trial underway for Alzheimer's

A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...

Alzheimer's disease & dementia created 6 hours ago | popularity not rated yet | comments 0

Drugs found to both prevent and treat Alzheimer's disease in mice

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.

Alzheimer's disease & dementia created May 21, 2013 | popularity 5 / 5 (7) | comments 0 | with audio podcast


When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs

Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...

Flu vaccine also linked to narcolepsy in adults, study reports

Finnish researchers unveiled new data Thursday to link the Pandemrix flu vaccine to a higher risk of the sleeping disorder narcolepsy in adults.

Heart healthy lifestyle may cut kidney disease patients' risk of kidney failure

Maintaining a heart healthy lifestyle may also help protect chronic kidney disease patients from developing kidney failure and dying prematurely, according to a study appearing in an upcoming issue of the Journal of the Am ...

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Farm bill: Senate rejects GMO labeling amendment

The Senate has overwhelmingly rejected an amendment allowing states to require labeling of genetically modified foods.

Diabetes' genetic underpinnings can vary based on ethnic background, studies say

Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.